Skip to main content

Table 3 Clinicopathologic parameters of the patients and hyperfibrinogenemia

From: Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients

Parameters Hyperfibrinogenemia P-value
Yes No
Age <56(362) 177(48.9 %) 185(51.1 %) 0.117
≥56(362) 155(42.8 %) 207(57.2 %)
FIGO Stage Early(62) 12(19.4 %) 50(80.6 %) <0.001
Advanced(662) 320(48.3 %) 342(51.7 %)
CA125 Level <500U/ml(157) 53(33.8 %) 104(66.2 %) 0.001
≥500U/ml(556) 272(48.9 %) 284(51.1 %)
Ascitesa No(85) 21(24.7 %) 64(75.3 %) <0.001
<500 ml(122) 22(18.0 %) 100(82.0 %)
≥500 ml(723) 289(56.0 %) 227(44.0 %)
Cytoreductionb R0(231) 70(30.3 %) 161(69.7 %) <0.001
R1(358) 179(50.0 %) 179(50.0 %)
R2(135) 83(61.5 %) 52(38.5 %)
Chemosensitivity Yes(474) 186(39.2 %) 288(60.8 %) <0.001
No(197) 118(59.5 %) 79(40.1 %)
  1. aSubgroup analyses: PNo vs <500ml = 0.296, PNo vs >500ml < 0.001, P<500 ml vs <500ml < 0.001
  2. bSubgroup analyses: PR0 vs R1  < 0.001, PR0 vs R2 < 0.001, PR1 vs R2 = 0.026
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us